More needs to be done by the private sector to optimize the drug discovery and development pipeline. In addition, significant efforts should also be focused on the understanding of mechanism of diseases, on the characterization of unexplored biochemical pathways and on the validation of new protein targets. Chemical genomics, which uses chemical probes to help understand the complexity of biological systems at the gene and protein levels, has proven in recent years to be an important tool. Experimental and computational chemical genomic screenings have been used by the private sector and recently also by academia and non-profit institutions for drug repurposing or repositioning to find new indications for known drugs. A detailed overview of the current initiatives in drug repurposing, initiated by the major 2 governmental funding agencies around the world is reported. The push towards greater efficiency is encouraging drug repurposing and other techniques in chemical genomics. Finding the best ways to improve translational research and accelerate the regulation of clinical phases means being able to launch safer drugs into the market faster.
INTRODUCTION
In the current post-genomic era, all the information obtained from Genome and Epigenome Projects in Human and other eukaryotic organisms must be translated from gene sequence level into 3D-protein space. More effort is needed to investigate and discover new intracellular biochemical pathways and protein targets linked to cancer and other diseases. Medicinal chemists have realized that the chemical space is biologically restrained. On the other hand, in the biological space, there is still much to be explored with the help of chemistry in order to better understand the mechanism of diseases and the action of current drugs.
Chemical genomics, which utilizes chemical probes to investigate the complexity of biological systems at the gene and protein levels, proved to be an important tool in the hands of interdisciplinary teams working in drug design and discovery, biomarker validation and protein target prediction [1] [2] [3] . An important concept fueling ideas, investments, initiatives and interdisciplinary collaborative efforts in chemical genomics is drug repurposing or repositioning, which has been extensively applied in the last 5-10 years by the private sector and recently also in non-profit/academic efforts [4] [5] [6] .
The idea behind drug repurposing is the use of old drugs (marketed FDA-approved drugs, FDAnon-approved drugs, or compounds which failed clinical trials) hitting the original or a different protein target for new indications. It started because of the need to speed up drug discovery and development pipelines which on average require 15 years and over a billion USD to bring a drug from a lab bench to the market and thus to the patients. Repurposed drugs would not only help make translational research steps faster but also would facilitate regulatory approval processes, increasing the chance of delivering drugs to the market [7, 8] .
Successful experimental drug repurposing techniques involving High-Throughput-Screening (HTS) or an in vivo zebrafish model have been already described [9, 10] . In addition, funding agencies have been encouraging the recent role of non-profit and academic centers and institutions in the use of drug repurposing in finding novel targets against neglected diseases [11] . Virtual Ligand Screening (VLS) of commercially available or purchasable drug repurposing databases have been employed in computational drug repurposing approaches [12, 13] . Database mining in systems biology offers a great opportunity to study side effects (offtarget side effects) of known drugs [14] .
Pitfalls and limitations of drug repurposing have been considered and significant efforts to correct them has been made so far.
The intention of this article is to report the current initiatives on drug repurposing in the field of chemical genomics, outlining different frameworks around the world, as shown in Fig. (1) .
DRUG REPURPOSING

Experimental
The case of Viagra was a successful repurposing case based on serendipity. were reported [18] .
Animal models can be also helpful in drug repurposing. The preclinical efficacy in vivo is key prerequisite for a molecule to enter human trials. Recently, the zebrafish model is becoming more attractive to the drug discovery community. This is due to the numerous advantages as a basic research model, per se, and for the variety of possible chemical genomics applications like protein target identification, genetic screens, phenotype-based target and lead discovery, Structure-Activity-Relationship (SAR) studies and toxicology prediction [19] . Since 2005, when Zon et al. published their interesting article [10] , considerable efforts by different academic groups possessing "in house" zebrafish facilities have been made [19, 20] .
A research domain for drug repurposing in academia is the study of neglected diseases [11, 21] .
The non-profit network Global Alliance for TB Drug Development is an inspiring initiative dedicated to the finding of new treatments through chemical genomics approaches for tubercolosis [22] . This is one of the recent examples where academia can successfully collaborate with private organizations. Solid initiatives have been recently begun by the National Cancer Institute (NCI) in the USA, as explained below.
Computational
Experimental approaches in drug repurposing have been ongoing but significant steps have been also made using computational techniques. Repurposing databases for in silico VLS are commercially available [23] . Pharmaceutical companies with their "in house" databases were the first to screen molecules computationally. In 2007, Bisson et al. published the first paper describing the successful use of in silico drug repurposing to find novel scaffolds inhibiting the Androgen Receptor (AR) [13] .
Later, Brian Shoichet and colleagues at the University of California, San Francisco (UCSF), published the important use of FDA-approved database of compounds for VLS techniques in order to predict off-side protein targets. This information is critical when we try to combine clinically more than one drug hitting different targets but aiming for the same phenotypic effect/indication [24, 25] .
In this particular context, database mining in systems biology might also represent other types of opportunities in drug repurposing. The publically available program PROMISCOUS is able to combine data on drugs, proteins and side effects [14] . In this way, researchers can then identify prospective new uses for known drugs by looking at the predictive interaction points available in the PROMISCOUS databases [14] .
DRUG REPURPOSING: CURRENT DEVELOPMENTS
USA
In January 2011 the US National Institutes of Health decided to create a strategic partnership between industry, government, academia and non-profit organizations to find future new treatments and cures [26] . The Learning Collaborative initiative combines the expertise of the NIH Chemical Genomics Center (NCGC) with its Therapeutics for Rare and Neglected Diseases (TRND) program, the Leukemia and Lymphoma Society (LLS) and the University of Kansas Cancer Center (KUCC) to discover and develop new drug therapies for rare blood cancers. The aims of this partnership are the discovery and the development of drugs for the treatment for rare blood cancer, whether new molecular entities (NME) or repurposed known drugs, whether approved or not [26] .
In addition, the involvement of academia in drug discovery programs is considered an important [32] or to discover new targets in cancer and other diseases [33, 34] . A successful case is the one recently published by the group of Yi Zhong [35] . By using EGFR known inhibitors Erlotinib and Gefitinib, the authors suggested that amyloid-ß may activate EGFR triggering a cascade of biochemical processes that damage neurons. Hence, EGFR is a preferred target for treating Aβ-induced memory loss [35] .
The private sector is not interested in investing too much time and money in molecules that do not stand a chance of becoming a drug. Hence, this becomes an opportunity for academia to step in.
As previously mentioned, academic groups are pushing for drug repurposing and chemical genomics on rare and neglected diseases because the expected limited return on investments make the discovery of new chemical entities (NCE) in these fields very challenging. The National Clinical Guideline Centre (NCGC) created the NCGC pharmaceutical collection of non-redundant approved molecules ready for both experimental and computational chemical genomics screenings [36] . Inspired by the previous successful repurposing stories of sildenafil (Viagra) and thalidomide, particular attention will not be focused on the interaction of a drug with its intended target but instead on a different organ and/or the action of a drug on a different target ("off-target" effects) [36, 37] .
Taiwan
Asia in general has a history based on the study of pharmaceutical active properties of natural The program IdTarget developed and published in 2012 is an available online as a web server for the identification of protein targets of small chemical molecules through VLS also using repurposing databases [40] . IdTarget screens rapidly against all protein structures deposited in the Protein Data Bank (PDB) [40] .
Switzerland
In 
EU
The EU FP7 emphasis on translational research (translation of basic discoveries in clinical applications) was a source of inspiration for innovative approaches in chemical genomics.
Chris Rundfeldt, Consultant, Preclinical Drug Development at Drug-Consult.Net said "Drug repurposing is not a primary goal for EU Funding but it can be the base for individual proposals.
At the moment, the EU is waiting to see the rate of success of drug repurposing campaigns initiated in US. There is still too much risk involved and the general concern that the use of old drugs for new indications will not produce a significant increase in the number of drugs into the market". One repurposing example is the currently on-going clinical trial for the treatment of stroke in which a drug commonly used to treat leukaemia (Glivec®) has shown promise in improving the therapeutic outcome [43] .
Michael Sundstrom, VP Drug Discovery Karolinska Development AB says "in Sweden we commonly follow EU Funding RoadMaps but at the same time we try to promote innovation by independent decisions and other funding sources. Especially, if that means taking significant steps towards optimal research and regulatory affairs which benefits public health in the country".
PITFALLS IN DRUG REPURPOSING: CAN WE DO SOMETHING ABOUT IT?
Drug repurposing may play an important role in optimizing and speeding up drug discovery and development pipelines. In addition, drug repurposing will help with the use of known compounds as chemical probes to understand mechanisms of diseases and to find novel protein targets.
As any other approach, drug repurposing faces a number of pitfalls. Some of them have been totally or partially sorted out but others certainly demand more effort from governments and the private sector.
In 2004 in the first big review, Ashburn et al. listed a number of disadvantages in drug repurposing [4] . These include public accessibility of data, regulatory standards, IP protection issues and required novel designs for clinical trials in case of new indications for a known compound.
Compared to only 5 years ago, the fact that several pharmaceutical companies decided to share data publically regarding a number of drugs was a significant step forward. "There is certainly still much to do to render clinical and physiological data on drugs accessible to researchers all over the world" says Ruben Abagyan of the University of California, San Diego (UCSD). "This would definitely help the development of more precise experimental and computational toxicity
